In Reply We thank Long et al for critically evaluating our study1 on the prognostic value of the lung immune prognostic index (LIPI) for patients treated for non–small cell lung cancer and for proposing 3 future clinical practice points, which we will address below. First, Long et al propose that different treatments require varying cutoff values for the neutrophil to lymphocyte ratio. Although we agree that it is important to use the appropriate cutoff and that results might vary depending on that value, our study evaluated baseline values prior to treatment. We showed that a prespecified neutrophil to lymphocyte ratio and lactate dehydrogenase level composite score can identify patients who are likely to have longer survival independent of treatment type (eg, immunotherapy, targeted therapy, chemotherapy). Our analysis did not aim to define a new cutoff value; rather, its intent was to validate the findings by Mezquita et al.2 Furthermore, Sorich et al,3 while our article was in press, published their findings, which similarly show that LIPI (using the original cutoff values) is prognostic for patients irrespective of whether they received immune checkpoint inhibitors or cytotoxic chemotherapy.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kazandjian D, Gong Y, Blumenthal GM. Application of the Lung Immune Prognostic Index From Research to Clinical Practice—Reply. JAMA Oncol. 2020;6(2):300–301. doi:10.1001/jamaoncol.2019.5157
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.